| Aspect | Key points | Recent sources (2023-2024 with first author/year) | URLs |
|---|---|---|---|
| Identity / domains | • Verified target is **human STAT1** matching UniProt **P42224**, a STAT-family transcription factor in IFN signaling.<br>• Conserved STAT architecture: **N-terminal, coiled-coil, DNA-binding, linker, SH2, C-terminal transactivation domain**.<br>• Canonical gene products include STAT1 homodimeric and STAT1-containing heterodimeric transcription factor functions, consistent with UniProt description of **ISGF3 component p91/p84**. (pqac-00000000, pqac-00000003) | Babadei 2024; Meesilpavikkai 2024 | https://doi.org/10.1016/j.jbc.2024.107771<br>https://doi.org/10.12932/ap-270124-1776 |
| Activation / PTMs | • Receptor-associated **JAKs** phosphorylate STAT1 on **Tyr701**, enabling dimerization and transcriptional activation.<br>• **Ser727** phosphorylation in the C-terminal region modulates transcriptional output; recent review also highlights context-dependent **Thr748** phosphorylation biology.<br>• GOF alleles often show **prolonged or increased pSTAT1** after cytokine stimulation due to altered phosphorylation/dephosphorylation dynamics. (pqac-00000000, pqac-00000008) | Babadei 2024; Meesilpavikkai 2024 | https://doi.org/10.1016/j.jbc.2024.107771<br>https://doi.org/10.12932/ap-270124-1776 |
| Complexes & DNA elements | • **STAT1 homodimers (GAF)** bind **GAS** elements, especially downstream of IFN-γ.<br>• **STAT1-STAT2-IRF9 (ISGF3)** binds **ISRE** elements, especially downstream of type I/III IFNs.<br>• Composite **ISRE+GAS** promoters function as regulatory switches integrating pSTAT1, pSTAT2, IRF9, and IRF1. (pqac-00000000, pqac-00000005, pqac-00000022) | Babadei 2024; Efstathiou 2024; Sekrecka 2023 | https://doi.org/10.1016/j.jbc.2024.107771<br>https://doi.org/10.3389/fimmu.2024.1395809<br>https://doi.org/10.1007/s00018-023-04830-8 |
| Localization | • In resting cells, STAT1 is largely cytoplasmic or shuttling in unphosphorylated/preassociated forms; after tyrosine phosphorylation it forms dimers that **translocate to the nucleus**.<br>• Nuclear import depends on interaction with **importin α/KPNA1**; RSV NS1 can block STAT1 nuclear translocation despite preserved phosphorylation.<br>• STAT1 executes its transcriptional role in the **nucleus** at IFN-responsive promoters/enhancers. (pqac-00000002, pqac-00000005) | Babadei 2024; Efstathiou 2024 | https://doi.org/10.1016/j.jbc.2024.107771<br>https://doi.org/10.3389/fimmu.2024.1395809 |
| Transcriptional programs / kinetics | • A cross-cell-type study summarized in review identified **975 ISGs**, with **166 core ISGs** robustly induced by IFN-I.<br>• Time-resolved multi-omics identified **319 IFNα-responsive integrated genes** and **286 IFNγ-inducible integrated genes** bound by STAT/IRF complexes; **108** were IFNα-specific and **75** IFNγ-specific.<br>• GAS genes tend to be **early**, ISRE genes more **intermediate/late**, while composite promoters show heterogeneous sustained responses driven by GAF, ISGF3, and IRF1. (pqac-00000018, pqac-00000022, pqac-00000023) | Sekrecka 2023; Babadei 2024 | https://doi.org/10.1007/s00018-023-04830-8<br>https://doi.org/10.1016/j.jbc.2024.107771 |
| Human genetic disorders & stats | • **STAT1 GOF** is the most common STAT1 defect: **>100 variants** reported in **>400 patients**; **CMC >60%**, and one review notes **98%** CMC in a series and **~half of all CMC** attributable to STAT1 GOF.<br>• A cohort of **274 patients** with STAT1 GOF showed broad infectious phenotypes: recurrent bacterial infections in **~75%**, pneumonias in **~50%**, viral infections in **~one-third**; another review notes bacterial infections in **more than half** and viral infections in **about half**.<br>• AR complete STAT1 deficiency is rare but severe: **24 patients** summarized in one review; a larger review cites **32 patients** with severe viral/mycobacterial disease, including universal BCGosis in one series; among **24 HSCT cases**, **10 transplanted** and **7 survived**. (pqac-00000008, pqac-00000009, pqac-00000012) | Meesilpavikkai 2024; Wang 2024; Ott 2023 | https://doi.org/10.12932/ap-270124-1776<br>https://doi.org/10.3390/pathogens13110955<br>https://doi.org/10.1007/s10875-023-01483-x |
| Therapeutic applications | • **JAK inhibitors** are the main targeted strategy in STAT1 GOF and related IFN-driven pathology; real-world adult case series showed **baricitinib** improved mucocutaneous disease, though infections/side effects occurred and one patient later required HSCT.<br>• In T1D models, JAK inhibition reduced IFN-driven **HLA-I hyperexpression**: baricitinib protected human beta-cell models; TYK2 inhibition also blocked IFN-induced HLA-I upregulation.<br>• Translational activity includes a reported **15-year-old STAT1 GOF** patient who became euglycemic off insulin for **12 months** on **ruxolitinib**, and the **BANDIT** placebo-controlled trial testing **baricitinib** in new-onset T1D. (pqac-00000011, pqac-00000024, pqac-00000025, pqac-00000030) | Borgström 2023; Russell 2023 | https://doi.org/10.1007/s10875-022-01351-0<br>https://doi.org/10.3389/fendo.2023.1270325 |


*Table: This table summarizes verified functional annotation evidence for human STAT1 (UniProt P42224), spanning molecular mechanism, localization, transcriptional programs, disease genetics, and current therapeutic applications. It emphasizes recent 2023-2024 sources and key quantitative findings useful for evidence-based gene annotation.*